Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin, to codevelop novel technologies that advance drug screening and discovery.
The agreement unites Merck’s strength in organoids and synthetic chemistry with Promega's market-leading assay and reporter technologies.
Together, the companies aim to develop assays capable of tracking cellular activity in real time using an innovative reporter system within three-dimensional (3D) cell cultures.
These 3D cell cultures, also called organoids, mimic human biology, whereby testing can be done in a model that is physiologically more relevant than traditional two-dimensional (2D) models.
“This partnership with Promega shows what is possible when two companies with a shared commitment to science join forces,” said Anand Nambiar, Head of Science & Lab Solutions for the Life Science business of Merck.
“By combining our organoid expertise with Promega's advanced reporter technology, we aim to enable high-throughput screening that helps researchers identify safer and more effective drug candidates for complex diseases such as cancer — and do it faster than ever before.”
“Collaborating with Merck allows us to push the boundaries of drug discovery,” said Tom Livelli, VP, Life Sciences Products & Services at Promega Corporation.
“By combining our technological strengths, we are helping to create more relevant and accessible models for drug discovery to enable new insights and eventually better outcomes for patients.”
In addition to the primary codevelopment agreement, Merck and Promega have signed a separate agreement to explore the integration of Merck’s Duolink with Promega’s HiBiT technologies.
This aims to create new workflows for studying the protein interactions inside cells, providing researchers with deeper insights into cellular signalling and supporting applications in both biologics and small-molecule drug discovery.
The partnership with Promega is one of the latest steps that Merck is taking to strengthen its leadership in next-generation biology and unite complementary expertise to deliver the next wave of breakthroughs in drug discovery.
In December 2024, Merck acquired HUB Organoids BV, a pioneer in organoid technology, which expanded Merck’s capabilities in 3D cell culture and enhanced its portfolio with HUB’s foundational patents, advanced model generation and high-throughput screening services.
These strategic moves position Merck as a leader in providing researchers with the tools needed to bridge the gap between laboratory discoveries and clinical success.